ArticleJournal of clinical pharmacology2016
Cerebrospinal fluid concentrations of tenofovir and emtricitabine in the setting of HIV-1 protease inhibitor-based regimens.
Open access · greenAbstract read
In one paragraph
Article in Journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Pharmacokinetic approaches to standardize antiviral exposure in cerebrospinal fluid.Pharmacotherapy · 2025Article
- The anti-HIV drug abacavir stimulates β-catenin activity in osteoblast lineage cells.JBMR plus · 2024Article
- CNS Viral Infections-What to Consider for Improving Drug Treatment: A Plea for Using Mathematical Modeling Approaches.CNS drugs · 2024Review
- Review
- Central nervous system disorders after use of dolutegravir: evidence from preclinical and clinical studies.Pharmacological reports : PR · 2023Review
- Clinical Reasoning: Rapidly Progressive Dementia in a Man With HIV Infection and Undetectable Plasma Viral Load.Neurology · 2023Article
- Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte-Derived Macrophages.Antimicrobial agents and chemotherapy · 2022Article
- Neuroinflammatory Profiling in SIV-Infected Chinese-Origin Rhesus Macaques on Antiretroviral Therapy.Viruses · 2022Article
- Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice.The Journal of antimicrobial chemotherapy · 2021Article
- Pharmacology of HIV Cure: Site of Action.Clinical pharmacology and therapeutics · 2021Review
- Targeting Beclin1 as an Adjunctive Therapy against HIV Using Mannosylated Polyethylenimine Nanoparticles.Pharmaceutics · 2021Article
- Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid.Southern African journal of HIV medicine · 2021Article
- Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.Journal of clinical pharmacology · 2020Article
- Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes.Journal of neurovirology · 2019Article
- Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid.Journal of pharmaceutical and biomedical analysis · 2018Article
- Risk for Speech and Language Impairments in Preschool Age HIV-exposed Uninfected Children With In Utero Combination Antiretroviral Exposure.The Pediatric infectious disease journal · 2018Article
- Determination of nucleosidic/tidic reverse transcriptase inhibitors in plasma and cerebrospinal fluid by ultra-high-pressure liquid chromatography coupled with tandem mass spectrometry.Clinical mass spectrometry (Del Mar, Calif.) · 2018Article
- Important roles of transporters in the pharmacokinetics of anti-viral nucleoside/nucleotide analogs.Expert opinion on drug metabolism & toxicologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Cecile D LahiriEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.
Kedria Reed-WalkerUniversity of Alabama-Birmingham School of Medicine, Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Birmingham, AL, USA.
Anandi N ShethEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.
Edward P AcostaUniversity of Alabama-Birmingham School of Medicine, Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Birmingham, AL, USA.
Aswani VunnavaEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.
Ighovwerha OfotokunEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases, Atlanta, GA, USA.
Emory University · USUniversity of Alabama at Birmingham · US
Funding
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0MAtlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8MAtlanta Clinical and Translational Science Institute (ACTSI) RenewalKL2TR000455 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$2.9MEliciting antibodies to probe native trimeric gp41 for HIV vaccine designR01AI114401 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI ZWICK, MICHAEL B · 2014 to 2018
$2.9MCharacterization and modulation of mucosal immunity for HIV prevention in womenK23AI114407 · NIAID · EMORY UNIVERSITY · PI SHETH, ANANDI NAYAN · 2014 to 2018
$898kNCATS NIH HHS KL2 TR000455NCATS NIH HHS KL2TR000455NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1TR000454NIAID NIH HHS 1K23AI114407-01NIAID NIH HHS K23 AI114407NIAID NIH HHS P30 AI050409NIAID NIH HHS P30AI050409NIAID NIH HHS R01 AI114401
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anti-HIV AgentsBlood-Brain BarrierCerebrospinal FluidEmtricitabineFemaleHIV-1HIV ProteaseHIV Protease InhibitorsHumansMaleMiddle AgedProdrugsRNA, ViralTenofovirAnti-HIV AgentsEmtricitabineHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1ProdrugsRNA, ViralTenofovircentral nervous systemclinical pharmacologyHIV/AIDS
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.